Nasopharyngeal carcinoma. IV. Evolution of complement‐fixing antibodies during the course of the disease

de-Thé, G; Sohier, R; Ho, J. H. C.; Freund, Robert

doi:10.1002/ijc.2910120208

Cited by 25 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could reflect either that EA, bound to be present in the virus-producing QMIR/WIL cells, could be detected by the CF test, as recently demonstrated (Lenoir and Berthelon, personal communication), or that structural antigens (VCA), known to be detectable by C F (Gerber and Birch, 1967;Walters and Pope, 1971) could be present in a monomeric soluble form in the 100,000 x g supernatant of the QMIR/WIL cell sonicate, as used in the CF test. Furthermore, the CF/S titres of NPC sera obtained with QMIR/WIL cells in the present study were significantly lower than those reported previously (de-The et al, 19736). The differences observed between the two studies could reflect variability in the amount of EBV antigens, detectable by CF tests (soluble, EA, and perhaps VCA), as produced by the QMIR/ WIL line at both periods.…”

Section: Cf-soluble Antigen Of Virus-producer or Nonproducer Linescontrasting

confidence: 88%

“…CF. Soluble antigen(s) was extracted from both non-virus-producer Raji cell line and from the virus producer QMIR/WIL cell line as previously described (Sohier and de-The, 1972;de-The et al, 19736). In brief, suspensions of approximately los cells/ml (80% viable cells) were washed in phosphate-buffered saline, frozen and thawed twice and sonicated for 2min with an MSE sonifier.…”

Section: Vcamentioning

confidence: 99%

See 1 more Smart Citation

Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other EBV antigens in Chinese patients

de-Thé

Ablashi

et al. 1975

Intl Journal of Cancer

View full text Add to dashboard Cite

Ninety-five sera from Chinese NPC patients in different stages of the disease, 38 sera from Chinese patients with other cancers, and 50 normal Chinese sera, were titrated for EBNA, VCA, EA and complement-fixing (CF/S) EBV-specific antibodies. The geometric mean (GMT) EBNA antibody titre of patients with NPC at stage I was found to be four times higher than that of normal individuals and increased in parallel with clinical deterioration. Antibody titres against EBNA did not correlate with either VCA or EA antibodies but, in general, correlated with CF/S antibodies. EA antibodies correlated relatively well with VCA antibodies and discriminated better than EBNA titre between NPC at stage I and controls.

show abstract

Section: Cf-soluble Antigen Of Virus-producer or Nonproducer Linescontrasting

confidence: 88%

Section: Vcamentioning

confidence: 99%

Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other EBV antigens in Chinese patients

de-Thé

Ablashi

et al. 1975

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Also, the incidence and GMT of IgG antibodies to D were distinctly reduced in the long-term survivors as compared to the untreated patients (Henle et al, 1973). Declines in VCA-specific IgG and anti-EBNA titers have been noted among patients who were followed for a 2-year period after therapy (de-The et al, 1973).…”

mentioning

confidence: 99%

Nasopharyngeal carcinoma: Significance of changes in epstein‐barr virus‐related antibody patterns following therapy

Henle

et al. 1977

Intl Journal of Cancer

160

View full text Add to dashboard Cite

Sera were collected a t intervals of 3 t o 8 months over a 4-t o 5-year period from more than 103 patients with nasopharyngeal carcinomas (NPC) and examined for their spectra and titers of antibodies t o Epstein-Barr virus (EBV)-related antigens. They were titrated for IgG, IgA and I g M antibodies t o EB viral capsid antigen (VCA), for IgG and IgA antibodies t o the D (diffuse) and R (restricted) components of the EBV-determined early antigen (EA) complex, and for antibodies t o the EBVassociated nuclear antigen (EBNA). In the as yet untreated patients the incidences and titers of most of the antibodies increased with the stage of the disease; i.e., essentially with the total tumor burden. Such increases were observed in individual patients whose disease ultimately progressed t o death, a t times well i n advance of the recognition of relapses o r metastases. Increases were not noted o r were only minor and delayed i n some fatal cases if the tumor extended t o the cranial cavity in the absence of significant involvement of cervical lymph nodes. I n contrast, patients who responded well t o therapy and remained clinically free of disease during the 4-o r 5-year observation period after, a t most, early minor relapses, showed gradual, steady declines in the titers of all antibodies except anti-EBNA. Thus, VCA-specific IgA and D-specific IgA and IgG became undetectable in t i m e in many of the patients. I n several long-term survivors the declines were arrested a t given levels o r a reversal t o increasing titers was noted which was followed i n time by detection of a recurrent tumor o r metastases in some cases, but not in others who remain under close observation. It would appear that serologic monitoring of NPC patients may warn of recurrent tumor activity well before it becomes clinically evident.

show abstract

“…tests have shown that patients with NPC usually possess high titers of antibody directed against EBV-specific virus capsid antigens (VCA) (1), membrane antigen (2), early antigen(s) (3), soluble antigen(s) (4), and nuclear antigen (5). In addition, EBV-specific antibody levels have been shown to be related to the clinical stage of the tumor (1,5).…”

Section: Data Obtained From a Variety Of Studies Support An Associatimentioning

confidence: 99%

Superinfection epithelial nasopharyngeal carcinoma cells with Epstein-Barr virus.

Glaser¹,

Thé²,

Lenoir³

et al. 1976

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Attempts were made to superinfect epithelial explant cell cultures prepared from nasopharyngeal carcinomas with Epstein-Barr virus. Virus-specific markers were observed in such cultures 3 days after superinfection. In addition, expression of Epstein-Barr virus early antigens was observed in epithelial cell explant cultures treated with iododeoxyuridine. The (2), early antigen(s) (3), soluble antigen(s) (4), and nuclear antigen (5). In addition, EBV-specific antibody levels have been shown to be related to the clinical stage of the tumor (1, 5).When NPC tumor biopsy specimens were assayed for EBV DNA by nucleic acid hybridization, virus-specific DNA was found in the specimens (6). Moreover, it has now been shown that both EBV genomes (7) and the EBV-associated nuclear antigen (EBNA) (8) are associated with the epithelial elements of NPC (9, 10) rather than with the infiltrating lymphoid cells (11).We have studied the expression and regulation of EBV in mammalian cells. To circumvent the inability of EBV to lytically infect (or transform) cells other than B (bone-marrow-derived) lymphocytes (12) 75-1525, 75-1531-1, 75-1531-2, and 75-1576) were cut into approximately 1 mm pieces. The tumor specimens were placed on glass coverslips in 13 mm plastic tissue culture plates (Falcon) which had been pretreated with calf serum to aid in attachment of explants. A small volume of RPMI 1640 medium supplemented with 20% fetal calf serum, 100 units of penicillin per ml, and 100 ,ug of streptomycin per ml was added to the tissue culture plates. Epithelial cells from the explants were allowed to grow out on glass coverslips prior to treatment or superinfection.Superinfection of NPC Epithelial Cells with EBV. Seven days after preparation of the NPC explants, the medium was changed and cells were grown in fresh RPMI 1640 medium, as previously described, for 24 hr. Coverslip explant cell cultures were infected with 0.2 ml aliquots containing 105 fluorescence-forming units (18)

show abstract

Nasopharyngeal carcinoma. IV. Evolution of complement‐fixing antibodies during the course of the disease

Abstract: Sequential sera from 37 patients with nasopharyngeal carcinoma ( N PC

Cited by 25 publications

References 9 publications

Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other EBV antigens in Chinese patients

Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other EBV antigens in Chinese patients

Nasopharyngeal carcinoma: Significance of changes in epstein‐barr virus‐related antibody patterns following therapy

Superinfection epithelial nasopharyngeal carcinoma cells with Epstein-Barr virus.

Contact Info

Product

Resources

About